Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Raloxifene hydrochloride.

K R Snyder1, N Sparano, J M Malinowski

  • 1Department of Pharmacy Practice, Wilkes University, Wilkes-Barre, PA 18766, USA. snyder@wilkes.edu

American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
|September 28, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Predicting Ozone Uptake from Meteorological and Environmental Variables.

Journal of the Air & Waste Management Association (1995)·2017
Same author

Is the combination of ibuprofen and caffeine effective for the treatment of a tension-type headache?

The Journal of family practice·2001
Same author

Rosiglitazone in the treatment of type 2 diabetes mellitus: a critical review.

Clinical therapeutics·2000
Same author

Which class of antidepressants is most effective and best tolerated by patients with major depression?

The Journal of family practice·2000
Same author

Extended anticoagulation for a first episode of idiopathic venous thromboembolism.

The Journal of family practice·1999
Same author

Atorvastatin: a hydroxymethylglutaryl-coenzyme A reductase inhibitor.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·1998
Same journal

Iodixanol-induced acute generalized exanthematous pustulosis: Cross-reactivity to other iodinated contrast media.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
Same journal

Sonrotoclax.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
Same journal

Bulevirtide Acetate-gmod.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
Same journal

Addressing feedback overload in pharmacy residents.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
Same journal

Development of a psychiatric pharmacy internship program at a children's hospital.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
Same journal

Integration of smart infusion pumps with electronic medical records improves safety and staff productivity at a large academic healthcare system.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
See all related articles

Raloxifene, a selective estrogen-receptor modulator (SERM), effectively prevents and treats osteoporosis in postmenopausal women. It also shows potential benefits for reducing breast cancer risk and improving cardiovascular markers.

Area of Science:

  • Pharmacology
  • Endocrinology
  • Women's Health

Background:

  • Osteoporosis is a significant health concern for postmenopausal women.
  • Selective estrogen-receptor modulators (SERMs) offer a targeted approach to managing estrogen-related conditions.

Purpose of the Study:

  • To review the pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and therapeutic role of raloxifene hydrochloride.
  • To evaluate raloxifene's potential in preventing and treating osteoporosis and its impact on breast cancer and cardiovascular health.

Main Methods:

  • Review of existing pharmacological and clinical trial data on raloxifene.
  • Analysis of raloxifene's mechanism of action as a SERM.

Main Results:

Related Experiment Videos

  • Raloxifene increases bone mineral density and reduces fracture risk in postmenopausal women.
  • It exhibits estrogen-agonist effects on bone and antagonist effects on breast and uterine tissues.
  • Potential benefits include reduced risk of breast cancer and positive effects on lipid profiles.

    • Conclusions:

    • Raloxifene is an effective alternative to hormone replacement therapy for osteoporosis in select postmenopausal women.
    • Further research is needed to confirm cardiovascular and breast cancer benefits.
    • The drug is generally well-tolerated, with hot flashes and leg cramps as common side effects; venous thromboembolism is a serious risk.